You are here: Industry Insights > Daiichi Sankyo

News List

Daiichi Sankyo fails to hold up influenza vaccine project biospectrumasia
May 20, 2019
Daiichi Sankyo Announces Update to H5N1 Influenza Vaccine National Project
FDA advisory panel votes against Daiichi Sankyo’s quizartinib pharmaceutical-technology
May 16, 2019
A cancer advisory committee of the US Food and Drug Administration (FDA) has voted against Daiichi Sankyo’s quizartinib, which is indicated to treat adults with relapsed / refractory FLT3-internal tandem duplication (ITD) acute myeloid leukaemia (AML).
Two Daiichi Sankyo drugs dealt a thumbs up and thumbs down by FDA advisory panel pharmafile
May 16, 2019
Daiichi Sankyo was left with a bittersweet taste in its mouth after it saw one of its drugs recommended for FDA approval by the US agency’s Oncologic Drugs Advisory Committee (ODAC) ...
Daiichi Sankyo launches hypertension drug in Japan biospectrumasia
May 15, 2019
The mineralocorticoid receptor is a receptor for steroid hormones that control the blood’s electrolyte balance
Daiichi Sankyo- AstraZeneca’s breast cancer drug reveals positive response biospectrumasia
May 09, 2019
Pivotal phase 2 DESTINY-Breast01 trial met primary endpoint, supporting global regulatory submission plan to start in first half of fiscal year 2019
AstraZeneca, Daiichi Sankyo's trastuzumab deruxtecan hits main goal of Phase II study in refractory HER2-positive metastatic breast cancer firstwordpharma
May 09, 2019
AstraZeneca and Daiichi Sankyo announced Wednesday that a pivotal Phase II study of trastuzumab deruxtecan in patients with refractory HER2-positive metastatic breast cancer met its primary endpoint ...
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need prnewswire
May 08, 2019
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca announced positive topline results for the pivotal phase 2 DESTINY-Breast01 trial of [fam-] trastuzumab deruxtecan (DS-8201).
Daiichi Sankyo sells Its Nihonbashi building in Japan biospectrumasia
April 28, 2019
As part of Daiichi Sankyo’s efforts toward the realization of its Vision for 2025 of being a “Global Pharma Innovator with competitive advantage in oncology”, the company is prioritizing resource allocation to the oncology therapeutic area
LifeArc licenses lead stage molecules to Daiichi Sankyo biospectrumasia
April 25, 2019
The licensing deal successfully concludes a research collaboration between LifeArc, Oxford University’s Nuffield Department of Clinical Neurosciences and Daiichi Sankyo.
LifeArc licenses discovery programme to Daiichi Sankyo pharmatimes
April 18, 2019
The deal successfully concludes a research collaboration between LifeArc, Oxford University’s Nuffield Department of ……

Previous page 1 2 3 4 5 6 7 8 Next page